RxDoctor Payments DataLook up a doctor →

Guilherme Silva, MD

Interventional Cardiology · Houston, TXNPI 1952579153

Payments from drug & device makers

$515,953in general payments, 2019–2025

Across 692 payments — averaging $745.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$214K
  • Abbott$181K
  • Medtronic$72K
  • W. L. Gore & Associates, Inc.$33K
  • Abiomed$10K
  • Boston Scientific$3K
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$4771%
  • Speaking & faculty fees$18,40634%
  • Grants$550%
  • Travel & lodging$18,44134%
  • Food & beverage$17,33932%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$515,953 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$195,101
Medicare patients
276
Services billed
1,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan103$109,398
EliquisApixaban76$71,208
BrilintaTicagrelor64$58,544
XareltoRivaroxaban12$17,252
Ranolazine ErRanolazine49$4,987
Prasugrel Hcl14$2,467
Metoprolol Succinate129$2,117
Amiodarone Hcl32$1,715
Enoxaparin Sodium27$1,572
Atorvastatin Calcium84$1,013
Isosorbide Mononitrate ErIsosorbide Mononitrate89$1,002
ClopidogrelClopidogrel Bisulfate93$750
Carvedilol59$584
Amlodipine Besylate28$354
Rosuvastatin Calcium18$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$79$109,398103 claims
PfizerEliquis$18$71,20876 claims
AstraZenecaBrilinta$32$58,54464 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →